Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC grew its stake in Cogent Biosciences, Inc. (NASDAQ:COGT) by 2,865.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 964,712 shares of the technology company’s stock after acquiring an additional 932,179 shares during the period. SG Americas Securities LLC owned about 0.87% of Cogent Biosciences worth $7,525,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Cogent Biosciences by 38.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,959 shares of the technology company’s stock worth $43,000 after buying an additional 1,104 shares during the period. Verition Fund Management LLC boosted its holdings in Cogent Biosciences by 7.5% during the 3rd quarter. Verition Fund Management LLC now owns 31,228 shares of the technology company’s stock valued at $337,000 after acquiring an additional 2,176 shares during the period. SkyView Investment Advisors LLC grew its position in Cogent Biosciences by 25.0% in the 2nd quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the technology company’s stock valued at $105,000 after acquiring an additional 2,500 shares in the last quarter. Values First Advisors Inc. acquired a new position in Cogent Biosciences in the 3rd quarter valued at about $32,000. Finally, Creative Planning lifted its position in shares of Cogent Biosciences by 29.6% during the third quarter. Creative Planning now owns 14,324 shares of the technology company’s stock worth $155,000 after purchasing an additional 3,272 shares in the last quarter.

Cogent Biosciences Stock Performance

Cogent Biosciences stock opened at $8.89 on Friday. The stock’s fifty day moving average is $8.46 and its two-hundred day moving average is $9.66. Cogent Biosciences, Inc. has a 1-year low of $4.28 and a 1-year high of $12.61.

Cogent Biosciences (NASDAQ:COGT) last posted its earnings results on Tuesday, November 12th. The technology company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07). During the same period in the previous year, the firm posted ($0.64) earnings per share. As a group, equities analysts forecast that Cogent Biosciences, Inc. will post -2.42 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. increased their target price on shares of Cogent Biosciences from $19.00 to $21.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Wedbush reiterated a “neutral” rating and issued a $11.00 target price on shares of Cogent Biosciences in a report on Monday, January 13th. Needham & Company LLC downgraded Cogent Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. Finally, HC Wainwright reduced their price target on Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Cogent Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $14.33.

Cogent Biosciences Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.